AZ launches branded YouTube channel, testimonial site

Share this article:

AstraZeneca (AZ) launched a branded YouTube channel today for its asthma drug Symbicort, as well as My Asthma Story (myasthmastory.com), a website calling for testimonial videos.

The YouTube channel and “vlog” (video blog) feature testimonial videos in widescreen, where patients describe their experiences with Symbicort. Some risk information scrolls across the bottom margin of the videos while they play, and a link to full PI information appears near the top of the channel page. Other fair balance information appears elsewhere on the page. The channel also directs consumers to myasthmastory.com, where Symbicort users are invited to upload videos about their own experiences with the drug.

According to Dana Settembrino, senior brand communications manager at AZ, the videos submitted on myasthmastory.com will be reviewed by a panel of legal, regulatory and compliance experts, with their selections appearing on the Symbicort YouTube channel.  Videos appearing on the YouTube channel are not open for comment by viewers.

The YouTube channel and the My Asthma Story website were created by Digitas and Cadient, and allow asthma-sufferers to “share patient stories about controlling asthma,” said Settembrino.  “[The channel and website] is a way to engage patients and maintain a conversation,” she said.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.